Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.38 |
| ▸ | CCR1 | P32246 | 7/20 | 0.38 |
| ▸ | DRD2 | P14416 | 7/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121740 | 0.86 | CCR1 (0.37) | CCR1DRD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14420129 | 0.83 | OPRM1 (0.39) | CCR1DRD2DRD3 | |
| SCHEMBL12121744 | 0.82 | DRD2 (0.39) | CCR1DRD2DRD3 | |
| SCHEMBL13824277 | 0.82 | CCR1 (0.40) | CCR1DRD2DRD3 | |
| SCHEMBL12121691 | 0.82 | CCR1 (0.41) | CCR1DRD2DRD3 | |
| SCHEMBL14420162 | 0.81 | CCR1 (0.54) | CCR3CCR1DRD2DRD3SMN1; SMN2 | |
| SCHEMBL13824486 | 0.80 | CCR1 (0.39) | CCR1DRD2 | |
| SCHEMBL13824278 | 0.78 | CCR1 (0.38) | CCR1DRD2 | |
| SCHEMBL13824271 | 0.77 | CCR1 (0.38) | CCR1DRD2DRD3 | |
| SCHEMBL14579853 | 0.77 | CCR1 (0.37) | CCR1DRD2DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR3 12/4885CCR1 9/4885DRD2 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.